Title:
ＮＫ－１／ＮＫ－３受容体二重アンタゴニストを含む新規な医薬製剤
Document Type and Number:
Japanese Patent JP7433252
Kind Code:
B2
Abstract:
The present invention generally relates to novel pharmaceutical formulations containing 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl) hexahydropyrazino [2,1-c] [1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide, methods of preparation thereof and their use in medical therapy.
Inventors:
Mike Trower
Mary Carr
David Elder
Monica Lazaro
Derek Bush
Mary Carr
David Elder
Monica Lazaro
Derek Bush
Application Number:
JP2020572615A
Publication Date:
February 19, 2024
Filing Date:
March 13, 2019
Export Citation:
Assignee:
Candy Therapeutics Limited
International Classes:
A61K31/5383; A61K9/48; A61K47/10; A61K47/14; A61K47/22; A61K47/26; A61K47/34; A61K47/44; A61P3/04; A61P5/24; A61P13/02; A61P15/12; A61P25/20; A61P25/22; A61P25/24
Domestic Patent References:
| JP2013503134A |
Foreign References:
| WO2016184829A1 |
Attorney, Agent or Firm:
Yasuhiko Murayama
Shinya Mihiro
Tatsuhiko Abe
Shinya Mihiro
Tatsuhiko Abe